Galectin Therapeutics Inc.

DB:PHPN Stock Report

Market Cap: €75.7m

Galectin Therapeutics Management

Management criteria checks 2/4

Galectin Therapeutics' CEO is Joel Lewis, appointed in Sep 2020, has a tenure of 4.67 years. total yearly compensation is $1.19M, comprised of 52.1% salary and 47.9% bonuses, including company stock and options. directly owns 1.32% of the company’s shares, worth €1.00M. The average tenure of the management team and the board of directors is 3.5 years and 9 years respectively.

Key information

Joel Lewis

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage52.1%
CEO tenure4.7yrs
CEO ownership1.3%
Management average tenure3.5yrs
Board average tenure9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Joel Lewis's remuneration changed compared to Galectin Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$1mUS$620k

-US$47m

Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$48m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$964kUS$574k

-US$45m

Sep 30 2023n/an/a

-US$45m

Jun 30 2023n/an/a

-US$40m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022US$974kUS$523k

-US$39m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$35m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$1mUS$500k

-US$31m

Sep 30 2021n/an/a

-US$31m

Jun 30 2021n/an/a

-US$29m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$1mUS$165k

-US$24m

Sep 30 2020n/an/a

-US$21m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$15m

Dec 31 2019US$189kn/a

-US$20m

Sep 30 2019n/an/a

-US$18m

Jun 30 2019n/an/a

-US$19m

Mar 31 2019n/an/a

-US$20m

Dec 31 2018US$55kn/a

-US$15m

Compensation vs Market: Joel's total compensation ($USD1.19M) is above average for companies of similar size in the German market ($USD499.53K).

Compensation vs Earnings: Joel's compensation has increased whilst the company is unprofitable.

CEO

Joel Lewis (54 yo)

4.7yrs

Tenure

US$1,189,674

Compensation

Mr. Joel Lewis serves as Chief Executive Officer and President at Galectin Therapeutics, Inc since September 2, 2020 and Director since December 14, 2017. He served as the Managing Director of Shareholder...

Leadership Team

NamePositionTenureCompensationOwnership
Joel Lewis
President4.7yrsUS$1.19m1.32%
€ 1.0m
Jack Callicutt
CFO, Treasurer & Corporate Secretary11.8yrsUS$716.95k0.11%
€ 81.1k
Khurram Jamil
Chief Medical Officerless than a yearUS$945.85k0.095%
€ 71.9k
Robert Tritt
General Counselno datano datano data
Jeff Katstra
Head of CMC & Pharmaceutical Development2.3yrsno datano data
Beth Knowles
Executive Assistant & Officer Managerno datano datano data

3.5yrs

Average Tenure

54yo

Average Age

Experienced Management: PHPN's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joel Lewis
President7.4yrsUS$1.19m1.32%
€ 1.0m
Gilbert Amelio
Independent Director16.3yrsUS$113.50k0.096%
€ 72.7k
Gilbert Omenn
Independent Director10.7yrsUS$108.00k0.13%
€ 98.6k
Richard Uihlein
Independent Chairman7.4yrsUS$98.00k16.36%
€ 12.4m
Marc Rubin
Independent Director13.6yrsUS$101.50k0.021%
€ 16.3k
Anatole Klyosov
 Co-founder & Member of the Scientific Boardno dataUS$203.69kno data
Harold Shlevin
Director5.4yrsUS$98.00k0.024%
€ 18.2k
Kevin Mayo
Member of the Scientific Boardno datano datano data
Kevin Freeman
Independent Vice Chairman of the Board14yrsUS$114.00k0.35%
€ 261.6k
Stephen A. Harrison
Member of Clinical Advisory Boardno datano datano data
Naga Chalasani
Member of Clinical Advisory Boardno datano datano data
Richard Zordani
Independent Director4.7yrsUS$113.00k0.071%
€ 53.8k

9.0yrs

Average Tenure

74yo

Average Age

Experienced Board: PHPN's board of directors are considered experienced (9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 17:05
End of Day Share Price 2025/05/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galectin Therapeutics Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeAscendiant Capital Markets LLC
Mayank MamtaniB. Riley Securities, Inc.
Vernon BernardinoDawson James Securities